{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T11:43:47Z","timestamp":1788608627508,"version":"build-2803163510"},"reference-count":46,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["gimjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Genetics in Medicine"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.gim.2022.07.026","type":"journal-article","created":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T06:32:09Z","timestamp":1662445929000},"page":"2318-2328","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Alpelisib for the treatment of PIK3CA-related head and neck lymphatic malformations and overgrowth"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1703-1546","authenticated-orcid":false,"given":"Tara L.","family":"Wenger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila","family":"Ganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Bull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Lutsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James T.","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlyn","family":"Zenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana M.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Dmyterko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezgi","family":"Mercan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giri M.","family":"Shivaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth D.","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bindschadler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Drusin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan N.","family":"Perkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ada","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall A.","family":"Bly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Dahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Bonilla-Velez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan A.","family":"Perkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.gim.2022.07.026_bib1","doi-asserted-by":"crossref","first-page":"12e","DOI":"10.1097\/01.prs.0000436822.26709.7c","article-title":"PIK3CA activating mutations in facial infiltrating lipomatosis","volume":"133","author":"Maclellan","year":"2014","journal-title":"Plast Reconstr Surg"},{"issue":"4","key":"10.1016\/j.gim.2022.07.026_bib2","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.jpeds.2014.12.069","article-title":"Lymphatic and other vascular malformative\/overgrowth disorders are caused by somatic mutations in PIK3CA","volume":"166","author":"Luks","year":"2015","journal-title":"J\u00a0Pediatr"},{"issue":"21","key":"10.1016\/j.gim.2022.07.026_bib3","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.129884","article-title":"Genotype correlates with clinical severity in PIK3CA-associated lymphatic malformations","volume":"4","author":"Zenner","year":"2019","journal-title":"JCI Insight"},{"issue":"2","key":"10.1016\/j.gim.2022.07.026_bib4","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/ajmg.a.36836","article-title":"PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation","volume":"167A","author":"Keppler-Noreuil","year":"2015","journal-title":"Am J Med Genet A"},{"issue":"7","key":"10.1016\/j.gim.2022.07.026_bib5","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1002\/ajmg.a.36552","article-title":"Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum","volume":"164A","author":"Keppler-Noreuil","year":"2014","journal-title":"Am J Med Genet A"},{"issue":"9","key":"10.1016\/j.gim.2022.07.026_bib6","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/gim.2016.220","article-title":"Molecular diagnosis of PIK3CA-related overgrowth spectrum (PROS) in 162 patients and recommendations for genetic testing","volume":"19","author":"Kuentz","year":"2017","journal-title":"Genet Med"},{"issue":"9","key":"10.1016\/j.gim.2022.07.026_bib7","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.87623","article-title":"PIK3CA-associated developmental disorders exhibit distinct classes of mutations with variable expression and tissue distribution","volume":"1","author":"Mirzaa","year":"2016","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.gim.2022.07.026_bib8","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/s13023-020-01480-y","article-title":"Detailed analysis of phenotypes and genotypes in megalencephaly-capillary malformation-polymicrogyria syndrome caused by somatic mosaicism of PIK3CA mutations","volume":"15","author":"Park","year":"2020","journal-title":"Orphanet J Rare Dis"},{"issue":"7","key":"10.1016\/j.gim.2022.07.026_bib9","doi-asserted-by":"crossref","DOI":"10.1002\/ccr3.4527","article-title":"Lymphangioma of the fetal neck within the PIK3CA-related-overgrowth spectrum (PROS): A case report","volume":"9","author":"Scharf","year":"2021","journal-title":"Clin Case Rep"},{"issue":"1","key":"10.1016\/j.gim.2022.07.026_bib10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/exd.12826","article-title":"Klippel-Trenaunay syndrome belongs to the PIK3CA-related overgrowth spectrum (PROS)","volume":"25","author":"Vahidnezhad","year":"2016","journal-title":"Exp Dermatol"},{"issue":"1","key":"10.1016\/j.gim.2022.07.026_bib11","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/cge.14027","article-title":"A\u00a0standard of care for individuals with PIK3CA-related disorders: an international expert consensus statement","volume":"101","author":"Douzgou","year":"2022","journal-title":"Clin Genet"},{"key":"10.1016\/j.gim.2022.07.026_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijporl.2021.110869","article-title":"Acetylsalicylic acid suppression of the PI3K pathway as a novel medical therapy for head and neck lymphatic malformations","volume":"151","author":"Bonilla-Velez","year":"2021","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"10.1016\/j.gim.2022.07.026_bib13","article-title":"Genotypes and phenotypes heterogeneity in PIK3CA-related overgrowth spectrum and overlapping conditions: 150 novel patients and systematic review of 1007 patients with PIK3CA pathogenetic variants","author":"Mussa","year":"2022","journal-title":"J\u00a0Med Genet"},{"issue":"9","key":"10.1016\/j.gim.2022.07.026_bib14","doi-asserted-by":"crossref","first-page":"e336","DOI":"10.1111\/jdv.15628","article-title":"Efficacy of sirolimus in the treatment of microcystic lymphatic malformation of the tongue","volume":"33","author":"Ghariani Fetoui","year":"2019","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.gim.2022.07.026_bib15","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/lary.26780","article-title":"Sirolimus as treatment for 19 patients with refractory cervicofacial lymphatic malformation","volume":"128","author":"Strychowsky","year":"2018","journal-title":"Laryngoscope"},{"issue":"11","key":"10.1016\/j.gim.2022.07.026_bib16","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1016\/j.jpedsurg.2019.12.021","article-title":"Effectiveness of sirolimus in the treatment of complex lymphatic malformations: single center report of 56 cases","volume":"55","author":"Tian","year":"2020","journal-title":"J\u00a0Pediatr Surg"},{"issue":"1","key":"10.1016\/j.gim.2022.07.026_bib17","first-page":"86","article-title":"Sirolimus in the treatment of vascular anomalies","volume":"27","author":"Triana","year":"2017","journal-title":"Eur J Pediatr Surg"},{"issue":"5","key":"10.1016\/j.gim.2022.07.026_bib18","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1089\/lrb.2018.0068","article-title":"Oral sirolimus: an option in the management of neonates with life-threatening upper airway lymphatic malformations","volume":"17","author":"Triana","year":"2019","journal-title":"Lymphat Res Biol"},{"key":"10.1016\/j.gim.2022.07.026_bib19","article-title":"Refractory head and neck lymphatic malformation in infants treated with sirolimus: a case series","volume":"11","author":"Wu","year":"2021","journal-title":"Front Oncol"},{"issue":"10","key":"10.1016\/j.gim.2022.07.026_bib20","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1177\/0003489415583330","article-title":"Successful treatment of macroglossia due to lymphatic malformation with sirolimus","volume":"124","author":"Yesil","year":"2015","journal-title":"Ann Otol Rhinol Laryngol"},{"issue":"5","key":"10.1016\/j.gim.2022.07.026_bib21","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/s41436-018-0297-9","article-title":"Safety and efficacy of low-dose sirolimus in the PIK3CA-related overgrowth spectrum","volume":"21","author":"Parker","year":"2019","journal-title":"Genet Med"},{"issue":"1","key":"10.1016\/j.gim.2022.07.026_bib22","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/cge.13550","article-title":"Old treatments for new genetic conditions: sirolimus therapy in a child affected by mosaic overgrowth with fibroadipose hyperplasia","volume":"96","author":"Leoni","year":"2019","journal-title":"Clin Genet"},{"issue":"1","key":"10.1016\/j.gim.2022.07.026_bib23","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1001\/archotol.132.1.93","article-title":"Lymphocytopenia in children with lymphatic malformation","volume":"132","author":"Tempero","year":"2006","journal-title":"Arch Otolaryngol Head Neck Surg"},{"issue":"20","key":"10.1016\/j.gim.2022.07.026_bib24","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer","volume":"380","author":"Andr\u00e9","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.gim.2022.07.026_bib25","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.annonc.2020.11.011","article-title":"Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1","volume":"32","author":"Andr\u00e9","year":"2021","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.gim.2022.07.026_bib26","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s40261-018-0696-3","article-title":"Unexpected benefit from alpelisib and fulvestrant in a woman with highly pre-treated ER-positive, HER2-negative PIK3CA mutant metastatic breast cancer","volume":"38","author":"Hoste","year":"2018","journal-title":"Clin Drug Investig"},{"issue":"2","key":"10.1016\/j.gim.2022.07.026_bib27","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.4475","article-title":"Alpelisib plus fulvestrant in PIK3CA-altered and PIK3CA-wild-type estrogen receptor-positive advanced breast cancer: a phase 1b clinical trial","volume":"5","author":"Juric","year":"2019","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.gim.2022.07.026_bib28","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/1078-0432.CCR-16-0134","article-title":"A\u00a0phase Ib study of alpelisib (BYL719), a PI3K\u03b1-specific inhibitor, with letrozole in ER+\/HER2- metastatic breast cancer","volume":"23","author":"Mayer","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.gim.2022.07.026_bib29","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s10549-020-05726-y","article-title":"Dermatologic adverse events related to the PI3K\u03b1 inhibitor alpelisib (BYL719) in patients with breast cancer","volume":"183","author":"Wang","year":"2020","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"10.1016\/j.gim.2022.07.026_bib30","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.annonc.2020.05.001","article-title":"Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer","volume":"31","author":"Rugo","year":"2020","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.gim.2022.07.026_bib31","first-page":"e349","article-title":"Diabetic ketoacidosis associated with alpelisib treatment of metastatic breast cancer","volume":"6","author":"Farah","year":"2020","journal-title":"AACE Clin Case Rep"},{"issue":"7711","key":"10.1016\/j.gim.2022.07.026_bib32","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/s41586-018-0217-9","article-title":"Targeted therapy in patients with PIK3CA-related overgrowth syndrome","volume":"558","author":"Venot","year":"2018","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.gim.2022.07.026_bib33","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.jpag.2019.07.003","article-title":"Alpelisib treatment for genital vascular malformation in a patient with congenital lipomatous overgrowth, vascular malformations, epidermal nevi, and spinal\/skeletal anomalies and\/or scoliosis (CLOVES) syndrome","volume":"32","author":"L\u00f3pez Guti\u00e9rrez","year":"2019","journal-title":"J\u00a0Pediatr Adolesc Gynecol"},{"issue":"3","key":"10.1016\/j.gim.2022.07.026_bib34","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00109-020-02030-6","article-title":"Somatic non-cancerous PIK3CA-related overgrowth syndrome treated with alpelisib in North America","volume":"99","author":"Garneau","year":"2021","journal-title":"J\u00a0Mol Med (Berl)"},{"issue":"6","key":"10.1016\/j.gim.2022.07.026_bib35","doi-asserted-by":"crossref","DOI":"10.1101\/mcs.a006147","article-title":"Cerebrofacial vascular metameric syndrome is caused by somatic pathogenic variants in PIK3CA","volume":"7","author":"Sheppard","year":"2021","journal-title":"Cold Spring Harb Mol Case Stud"},{"issue":"2","key":"10.1016\/j.gim.2022.07.026_bib36","article-title":"Somatic activating BRAF variants cause isolated lymphatic malformations","volume":"3","author":"Zenner","year":"2022","journal-title":"HGG Adv"},{"issue":"1","key":"10.1016\/j.gim.2022.07.026_bib37","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41436-020-00943-8","article-title":"Cell-free DNA as a diagnostic analyte for molecular diagnosis of vascular malformations","volume":"23","author":"Zenner","year":"2021","journal-title":"Genet Med"},{"issue":"5","key":"10.1016\/j.gim.2022.07.026_bib38","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1001\/archotol.1995.01890050065012","article-title":"Lymphatic malformations of the head and neck. A proposal for staging","volume":"121","author":"de Serres","year":"1995","journal-title":"Arch Otolaryngol Head Neck Surg"},{"issue":"4","key":"10.1016\/j.gim.2022.07.026_bib39","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1177\/0194599815594776","article-title":"The lymphatic malformation function (LMF) instrument","volume":"153","author":"Kirkham","year":"2015","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"1","key":"10.1016\/j.gim.2022.07.026_bib40","first-page":"e037","article-title":"Quantifying head and neck lymphatic malformation volume and composition during treatment","volume":"3","author":"Konuthula","year":"2022","journal-title":"J\u00a0Vasc Anom"},{"issue":"6","key":"10.1016\/j.gim.2022.07.026_bib41","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1002\/lary.29180","article-title":"Active observation as an alternative to invasive treatments for pediatric head and neck lymphatic malformations","volume":"131","author":"Bonilla-Velez","year":"2021","journal-title":"Laryngoscope"},{"issue":"614","key":"10.1016\/j.gim.2022.07.026_bib42","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abg0809","article-title":"Alpelisib administration reduced lymphatic malformations in a mouse model and in patients","volume":"13","author":"Delestre","year":"2021","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.gim.2022.07.026_bib43","first-page":"e038","article-title":"Clinical response to PI3K-\u03b1 inhibition in a cohort of children and adults with PIK3CA-related overgrowth spectrum disorders","volume":"3","author":"Raghavendran","year":"2022","journal-title":"J\u00a0Vasc Anom"},{"key":"10.1016\/j.gim.2022.07.026_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2021.732836","article-title":"PIK3CA-related overgrowth spectrum from diagnosis to targeted therapy: a case of CLOVES syndrome treated with alpelisib","volume":"9","author":"Pagliazzi","year":"2021","journal-title":"Front Pediatr"},{"issue":"5","key":"10.1016\/j.gim.2022.07.026_bib45","first-page":"671","article-title":"Pulmonary vein stenosis associated with germline PIK3CA mutation","volume":"9","author":"Yung","year":"2022","journal-title":"Children (Basel)"},{"issue":"3","key":"10.1016\/j.gim.2022.07.026_bib46","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20212148","article-title":"Treatment of two infants with PIK3CA-related overgrowth spectrum by alpelisib","volume":"219","author":"Morin","year":"2022","journal-title":"J\u00a0Exp Med"}],"container-title":["Genetics in Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098360022008917?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098360022008917?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:53:01Z","timestamp":1761097981000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098360022008917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":46,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S1098360022008917"],"URL":"https:\/\/doi.org\/10.1016\/j.gim.2022.07.026","relation":{},"ISSN":["1098-3600"],"issn-type":[{"value":"1098-3600","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alpelisib for the treatment of PIK3CA-related head and neck lymphatic malformations and overgrowth","name":"articletitle","label":"Article Title"},{"value":"Genetics in Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gim.2022.07.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American College of Medical Genetics and Genomics. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}